Aurobindo Pharma has reported results for the fourth quarter (Q4FY26) and year ended March 31, 2026.
The company has reported 69.59% jump in its net profit at Rs 692.23 crore for the fourth quarter ended March 31, 2026 as compared to Rs 408.17 crore for the same quarter in the previous year. The total income of the company has increased by 5.43% at Rs 3,000.64 crore for Q4FY26 as compared to Rs 2,845.97 crore for the corresponding quarter previous year.
On consolidated basis, the company has reported 1.97% rise in its net profit at Rs 921.26 crore for the fourth quarter ended March 31, 2026 as compared to Rs 903.47 crore for the same quarter in the previous year. The total income of the company increased by 5.32% at Rs 8,970.38 crore for Q4FY26 as compared to Rs 8,516.93 crore for the corresponding quarter previous year.
For the year ended March 31, 2026, the company has reported 38.24% rise in its net profit at Rs 2,414.80 crore as compared to Rs 1,746.79 crore for the previous year. The total income of the company has increased by 4.42% at Rs 11,759.25 crore for year under review as compared to Rs 11,261.42 crore for year ended March 31, 2025.
For the year ended March 31, 2026, on the consolidated basis, the company has reported marginal rise in its net profit at Rs 3,504.75 crore as compared to Rs 3,485.88 crore for the previous year. The total income of the company increased by 5.56% at Rs 34,145.17 crore for year under review as compared to Rs 32,345.58 crore for year ended March 31, 2025.
